LEXX (Lexaria Bioscience) Beneish M-Score: -3.43 (As of Jun. 25, 2026)


LEXX Lexaria Bioscience Corp LEXX
28 GF Score
Price $0.54
GF Value $0.75
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Lexaria Bioscience Beneish M-Score?

Lexaria Bioscience LEXX -3.61% 28 Beneish M-Score is -3.43 as of Jun. 25, 2026. GuruFocus rates LEXX with a GF Score™ of 28/100 and a GF Value™ of $0.75 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 831 Biotechnology companies, Lexaria Bioscience ranks better than 82.19% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.43 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Lexaria Bioscience's Beneish M-Score or its related term are showing as below:

LEXX' s Beneish M-Score Range Over the Past 10 Years
Min: -13.58   Med: -3.71   Max: 2.92
Current: -3.43

During the past 13 years, the highest Beneish M-Score of Lexaria Bioscience was 2.92. The lowest was -13.58. And the median was -3.71.


Lexaria Bioscience Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Lexaria Bioscience's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexaria Bioscience Beneish M-Score Chart

Lexaria Bioscience Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.88 -3.85 -4.43 -2.52 -3.49

Lexaria Bioscience Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.55 -5.30 -3.49 -6.33 -3.43

LEXX vs MBRX, ICU, INTI: Beneish M-Score Comparison

For the Biotechnology subindustry, Lexaria Bioscience's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexaria Bioscience Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Lexaria Bioscience's Beneish M-Score falls into.


LEXX
28GF Score
Lexaria Bioscience Corp LEXX
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lexaria Bioscience Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Lexaria Bioscience for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.1814+0.528 * 0.9943+0.404 * 0.8574+0.892 * 0.6996+0.115 * 0.7482
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.2342+4.679 * -0.012795-0.327 * 0.1934
=-3.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Feb26) TTM:Last Year (Feb25) TTM:
Total Receivables was $0.04 Mil.
Revenue was 0.02 + 0 + 0.174 + 0.174 = $0.37 Mil.
Gross Profit was 0.02 + 0 + 0.174 + 0.174 = $0.37 Mil.
Total Current Assets was $5.77 Mil.
Total Assets was $6.49 Mil.
Property, Plant and Equipment(Net PPE) was $0.34 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.09 Mil.
Selling, General, & Admin. Expense(SGA) was $4.09 Mil.
Total Current Liabilities was $0.22 Mil.
Long-Term Debt & Capital Lease Obligation was $0.06 Mil.
Net Income was -1.45 + -1.595 + -2.696 + -3.789 = $-9.53 Mil.
Non Operating Income was 0 + -0.022 + -0.011 + -0.04 = $-0.07 Mil.
Cash Flow from Operations was -2.164 + -0.984 + -2.642 + -3.584 = $-9.37 Mil.
Total Receivables was $0.33 Mil.
Revenue was 0.174 + 0.184 + 0.084 + 0.084 = $0.53 Mil.
Gross Profit was 0.174 + 0.181 + 0.084 + 0.084 = $0.52 Mil.
Total Current Assets was $7.72 Mil.
Total Assets was $8.68 Mil.
Property, Plant and Equipment(Net PPE) was $0.36 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.07 Mil.
Selling, General, & Admin. Expense(SGA) was $4.73 Mil.
Total Current Liabilities was $1.82 Mil.
Long-Term Debt & Capital Lease Obligation was $0.09 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.042 / 0.368) / (0.331 / 0.526)
=0.11413 / 0.629278
=0.1814

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.523 / 0.526) / (0.368 / 0.368)
=0.994297 / 1
=0.9943

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (5.77 + 0.335) / 6.487) / (1 - (7.724 + 0.358) / 8.678)
=0.058887 / 0.068679
=0.8574

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.368 / 0.526
=0.6996

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.066 / (0.066 + 0.358)) / (0.088 / (0.088 + 0.335))
=0.15566 / 0.208038
=0.7482

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(4.086 / 0.368) / (4.732 / 0.526)
=11.103261 / 8.996198
=1.2342

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.062 + 0.215) / 6.487) / ((0.094 + 1.822) / 8.678)
=0.042701 / 0.220788
=0.1934

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-9.53 - -0.073 - -9.374) / 6.487
=-0.012795

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Lexaria Bioscience has a M-score of -3.43 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.43 mean?
Lexaria Bioscience (LEXX) has a Beneish M-Score of -3.43 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Lexaria Bioscience and its competitors. According to the industry distribution chart, Lexaria Bioscience ranks #148 out of 831 companies in the Biotechnology industry, placing it in the top 17.8%.
Is Lexaria Bioscience's Beneish M-Score too high?
Lexaria Bioscience's current Beneish M-Score is -3.43. Based on the distribution chart, Lexaria Bioscience ranks #148 out of 831 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lexaria Bioscience has a GF Score™ of 28/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lexaria Bioscience's Beneish M-Score compare to MBRX and ICU?
According to the Biotechnology industry distribution chart, Lexaria Bioscience ranks #148 out of 831 companies for Beneish M-Score. This places Lexaria Bioscience in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Lexaria Bioscience and its competitors. Lexaria Bioscience's current Beneish M-Score is -3.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexaria Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Lexaria Bioscience (LEXX) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.75, compared to a current price of $0.54 — trading 27.7% below its estimated fair value. The current Beneish M-Score is -3.43. Lexaria Bioscience's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Lexaria Bioscience (LEXX), the current Beneish M-Score is -3.43 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lexaria Bioscience (LEXX) Overvalued in 2026?

Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be undervalued. The current stock price of $0.54 is trading 27.7% below its estimated GF Value™ of $0.75. GuruFocus considers Lexaria Bioscience to be Modestly Undervalued.

Key valuation signals for LEXX:

  • Beneish M-Score: -3.43
  • GF Value™: $0.75 vs. price of $0.54 (27.7% below fair value)
  • GF Score™: 28/100 with 3 warning signs

No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lexaria Bioscience Business Description

Address 740 McCurdy Road, No. 100, Kelowna, BC, CAN, V1X 2P7
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
28GF Score

Get the complete analysis for LEXX

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.54
Price
$0.75
GF Value